首页> 外文OA文献 >Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week, Flexible-Dose, Open-Label Extension to a 40-Week, Double-Blind, Randomised, Placebo-Controlled Core Study

【2h】

Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week, Flexible-Dose, Open-Label Extension to a 40-Week, Double-Blind, Randomised, Placebo-Controlled Core Study

机译：患有注意力缺陷多动障碍的成年人的哌醋甲酯修饰释放长效制剂（MPH-LA）的长期（1年）安全性和有效性：26周，灵活剂量，开放标签扩展到40-周，双盲，随机，安慰剂对照核心研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类
入库时间 2022-08-20 20:27:51

相似文献

外文文献

1. Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week, Flexible-Dose, Open-Label Extension to a 40-Week, Double-Blind, Randomised, Placebo-Controlled Core Study [J] . Ginsberg Y., Arngrim T., Philipsen A., CNS drugs . 2014,第10期

机译：患有注意力缺陷多动障碍的成年人的哌醋甲酯修饰释放长效制剂（MPH-LA）的长期（1年）安全性和有效性：26周，灵活剂量，开放标签扩展至40-周，双盲，随机，安慰剂对照核心研究
2. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: Randomised double-blind placebo-controlled trial with open-label extension [J] . GinsbergY., LindeforsN. The British journal of psychiatry : . 2012,第1期

机译：哌醋甲酯治疗患有注意力不足过动症的成年男性囚犯：开放标签扩展的随机双盲安慰剂对照试验
3. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension [J] . Nils Lindefors, Ylva Ginsberg The British journal of psychiatry : . 2012,第1期

机译：哌醋甲酯治疗患有注意力不足过动症的成年男性囚犯：随机双盲安慰剂对照试验，采用开放标签扩展
4. Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week Flexible-Dose Open-Label Extension to a 40-Week Double-Blind Randomised Placebo-Controlled Core Study [O] . Y. Ginsberg, T. Arngrim, A. Philipsen, -1

机译：患有注意力缺陷多动障碍的成年人的哌醋甲酯修饰释放长效制剂（MPH-LA）的长期（1年）安全性和有效性：26周灵活剂量开放标签扩展到40-周双盲随机安慰剂对照核心研究
5. Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day) [O] . Istvan Bitter 2012

机译：广义焦虑症非抑郁患者的长期疗效和治疗症的安全性。一个26周的随机双盲安慰剂控制并行组在含有胍盐碱的开放标签期间（25毫克/天，致盲剂量调节至50毫克/天）

Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week, Flexible-Dose, Open-Label Extension to a 40-Week, Double-Blind, Randomised, Placebo-Controlled Core Study

著录项

相似文献

相关主题

期刊订阅